Interestingly, in a mouse model of influenza-induced exacerbation of allergic asthma only IL-33-specific neutralization resulted in improved AHR, prevented body weight loss and accumulation of inflammatory cells in the lungs, whereas combined administration of anti-TSLP and anti-IL-33 did not provide any additional benefits as compared to anti-IL-33 monotherapy (49). This evidence concerns the gene TSLP and allergic asthma.